- Home
- KPRX vs FBRX Comparison
KPRX vs FBRX Comparison
Compare KPRX & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- FBRX
- Stock Information
- Founded
- KPRX 1998
- FBRX N/A
- Country
- KPRX United States
- FBRX United States
- Employees
- KPRX N/A
- FBRX N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- FBRX Biotechnology: Pharmaceutical Preparations
- Sector
- KPRX Health Care
- FBRX Health Care
- Exchange
- KPRX Nasdaq
- FBRX Nasdaq
- Market Cap
- KPRX 9.8M
- FBRX 59.5M
- IPO Year
- KPRX N/A
- FBRX N/A
- Fundamental
- Price
- KPRX $3.19
- FBRX $5.91
- Analyst Decision
- KPRX Strong Buy
- FBRX Strong Buy
- Analyst Count
- KPRX 1
- FBRX 4
- Target Price
- KPRX $10.00
- FBRX $77.58
- AVG Volume (30 Days)
- KPRX 41.2K
- FBRX 21.6K
- Earning Date
- KPRX 03-24-2025
- FBRX 03-17-2025
- Dividend Yield
- KPRX N/A
- FBRX N/A
- EPS Growth
- KPRX N/A
- FBRX N/A
- EPS
- KPRX 1.69
- FBRX N/A
- Revenue
- KPRX $16,020,000.00
- FBRX N/A
- Revenue This Year
- KPRX N/A
- FBRX N/A
- Revenue Next Year
- KPRX N/A
- FBRX N/A
- P/E Ratio
- KPRX $1.89
- FBRX N/A
- Revenue Growth
- KPRX N/A
- FBRX N/A
- 52 Week Low
- KPRX $2.91
- FBRX $4.11
- 52 Week High
- KPRX $6.48
- FBRX $28.68
- Technical
- Relative Strength Index (RSI)
- KPRX 42.17
- FBRX 21.73
- Support Level
- KPRX $2.91
- FBRX $6.51
- Resistance Level
- KPRX $3.53
- FBRX $9.90
- Average True Range (ATR)
- KPRX 0.18
- FBRX 1.09
- MACD
- KPRX -0.01
- FBRX -0.16
- Stochastic Oscillator
- KPRX 33.41
- FBRX 0.00
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA).